Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$18.4 Million In User Fees Left In CDRH’s Coffers, How Long Will It Last?

This article was originally published in The Gray Sheet

Executive Summary

The device center says it had $18.4 million in user fees remaining as of Oct. 1 to continue its work focused solely on user-fee funded activities, but the agency is unsure how long the funds will last if the government shutdown continues.

You may also be interested in...



News Briefs: Teleflex Acquires Vidacare; Integra Buys Covidien’s DuraSeal Line

Teleflex buys Vidacare Corp. for $262.5 million. Integra LifeSciences acquires Covidien’s Confluent Surgical product line, including the DuraSeal products, for $235 million, plus up to $30 million in milestone payments. W.L. Gore ordered to pay more than $850 million to C.R. Bard to partially resolve a long-running patent dispute. More news.

Addressing The Device Backlog: Government Shutdown Ends, Now FDA Has To Catch Up

After the shutdown, FDA staff are facing a backlog of fiscal year 2014 device submissions. The agency is working on a plan and assessing its ability to meet its MDUFA III commitments. The bigger concern, however, may be the regulatory uncertainty created by the short-term deal in Congress.

Addressing The Backlog: Government Shutdown Ends, Now FDA Has To Catch Up

After the two-week shutdown, FDA staff are facing a backlog of fiscal year 2014 device submissions. The agency says it is working on a plan and assessing its ability to meet its MDUFA III commitments. The bigger concern, however, may be the regulatory uncertainty created by the short-term deal in Congress.

Related Content

Topics

UsernamePublicRestriction

Register

MT032490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel